Progress of driving gene rare mutations in advanced non-small cell lung cancer
10.3760/cma.j.cn115355-20190909-00403
- VernacularTitle:驱动基因少见突变晚期非小细胞肺癌的研究进展
- Author:
Ziwei DING
1
;
Junhui ZHAO
Author Information
1. 青海大学附属医院肿瘤内科，西宁 810000
- From:
Cancer Research and Clinic
2020;32(9):662-665
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the continuous development of driving gene rare mutations of advanced non-small cell lung cancer (NSCLC) patients and molecular biology technology, molecular detection and individualized therapy have become standard diagnosis and treatment strategies for patients with advanced NSCLC. The driving gene of NSCLC has become a research focus. The development of molecular detection technology, the discovery of new driving gene and the continuous emergence of new drugs have made the treatment of rare target mutations in NSCLC increasingly precise. This article retrieves and screens out the documents published in recent years which are related to driving gene rare mutations in patients with advanced NSCLC, and analyzes the relevant research progress. It is hoped that more reasonable and accurate treatment plans can be formulated for NSCLC patients to guide the clinical research of NSCLC treatment.
